Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.
- DOI
- 10.1016/j.jtocrr.2021.100206
- Published
- 2021 Sep
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2021.100206,
title = {Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.},
author = {Park K and Tan DSW and Su WC and Cho BC and Kim SW and Lee KH and Wang CC and Seto T and Huang DC and Jung HH and Hsu MC and Bogenrieder T and Lin CC},
year = {2021},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2021.100206},
url = {https://doi.org/10.1016/j.jtocrr.2021.100206}
}RIS
TY - JOUR TI - Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors. AU - Park K AU - Tan DSW AU - Su WC AU - Cho BC AU - Kim SW AU - Lee KH AU - Wang CC AU - Seto T AU - Huang DC AU - Jung HH AU - Hsu MC AU - Bogenrieder T AU - Lin CC PY - 2021 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2021.100206 UR - https://doi.org/10.1016/j.jtocrr.2021.100206 ER -
APA
K, P., DSW, T., WC, S., BC, C., SW, K., KH, L., CC, W., T, S., DC, H., HH, J., MC, H., T, B., & CC, L. (2021). Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2021.100206
Source records
- pubmed · retrieved 2026-09-26T19:43:48.984Z